Table V.
Effectiveness of apremilast
| Timepoint (months) | PASI, mean (SD) |
PASI reduction category, mean (SD) |
||
|---|---|---|---|---|
| PP | LOCF | PP | LOCF | |
| 0 | 6.48 (6.37) | 6.48 (6.37) | NA | NA |
| 3 | 3.76 (5.58) | 5.04 (5.96) | 3.79 (1.33) | 4.25 (1.26) |
| 6 | 3.24 (5.02) | 4.85 (5.94) | 3.40 (1.46) | 4.07 (1.48) |
| 12 | 2.84 (6.13) | 4.79 (6.21) | 3.09 (1.54) | 4.03 (1.54) |
| 24 | 2.14 (4.15) | 5.03 (6.43) | 2.98 (1.50) | 4.03 (1.58) |
| 36 | 2.16 (4.50) | 5.12 (6.46) | 2.11 (1.14) | 4.03 (1.62) |
| 48 | NA | 5.12 (6.48) | 2.39 (0.55) | 4.04 (1.61) |
LOCF, Last observation carried forward/worst-case scenario; NA, not applicable; PASI, psoriasis area and severity index; PP, per protocol; SD, standard deviation. PASI reduction category is defined as follows: 5 (<50%), 4 (50% to <75%), 3 (75% to <90%), 2 (90% to <100%) and 1 (100%).